Highlights:

• Strong buying interest has lifted three healthcare-focused stocks in the latest trading session.
• Improving profitability, strategic execution and capital management are shaping investor sentiment.
• Recent financial results provide fresh catalysts for investors assessing the sector.

Stocks In Focus:

Three stocks have attracted strong buying interest on the ASX, with companies recording sizeable gains during the latest session. 

• Australian Clinical Labs Limited (ASX: ACL) rose 14.468% to AU$2.690
• L1 Group Limited (ASX: L1G) advanced 6.334% to AU$1.175.
• Healius Limited (ASX: HLS) also climbed 11.874% to AU$0.447

The moves come as investors assess company-specific developments alongside broader opportunities across the healthcare and investment-management landscape. While ACL and L1G have released fresh financial information, no new announcement has been considered for HLS in this article.

ACL Delivers a Resilient FY26

Australian Clinical Labs released its FY26 financial results on 17 August 2026, reporting improved underlying profitability despite subdued pathology market conditions, Medicare funding changes and inflationary pressures. Underlying EBIT increased 1.7% to AU$69.2 million, while the underlying EBIT margin expanded to 9.4% from 9.2% a year earlier. Underlying NPAT also climbed 4.3% to AU$35.5 million. For FY27, ACL expects revenue between AU$745 million and AU$765 million, with underlying EBIT forecast at AU$67 million to AU$73 million. The company also declared a fully franked final dividend of 9.25 cents per share, payable on 23 September 2026.

L1G Posts a Major Earnings Lift

L1 Group reported a substantial improvement in FY26 earnings. Underlying NPAT reached AU$188.8 million, up 97%, while underlying EBITDA increased 102% to AU$287.4 million. Revenue rose 49% to AU$385.9 million as operating expenses declined approximately 15%. Funds under management increased approximately 17% to AU$19.1 billion, while merger synergies reached AU$31.7 million. L1 Group has lifted its total synergy target to AU$43 million, with further benefits expected during FY27.

HLS Joins the Healthcare Rally

Healius Limited gained 11.874% to AU$0.447, adding another strong move to the healthcare sector. With no new company announcement being considered for this stock, the latest price action is presented as a market-performance update rather than being linked to a specific corporate catalyst.

What Could Investors Watch Next?

The latest movements highlight how quickly investor sentiment can shift when stronger earnings, improving operational performance or expectations around future growth come into focus. ACL’s FY27 targets and L1G’s post-merger earnings momentum provide identifiable catalysts, while HLS’s sharp price increase demonstrates continued market interest in healthcare stocks.As investors look ahead, the sustainability of earnings growth, margin performance and future corporate developments could determine whether these recent gains develop into longer-term momentum.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au